Subjects 26-83 years old will receive CR500 SINGLE-DOSE GEL given for the treatment of osteoarthritis of the knee over a 4-week time period. The primary objective of the study is to evaluate the effect of CR500 SINGLE-DOSE GEL in the treatment of KOA.
Single arm clinical investigation, post-market confirmatory interventional to assess performance, safety and tolerability of CR500 SINGLE-DOSE GEL medical device in patients with knee osteoarthritis (KOA).